T. Rowe Price Associates
ABCL icon

T. Rowe Price Associates’s AbCellera Biologics ABCL Stock Holding History

T. Rowe Price Associates’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.5M Buy
+1,587,870
New +$7.76M ﹤0.01% 1278
2023
Q2 		– Sell
-39,916
Closed -$301K – 2889
2023
Q1 		$301K Buy
39,916
+3,953
+11% +$35.9K ﹤0.01% 2340
2022
Q4 		$364K Buy
35,963
+2,249
+7% +$26K ﹤0.01% 2296
2022
Q3 		$334K Buy
33,714
+13,955
+71% +$153K ﹤0.01% 2330
2022
Q2 		$210K Buy
+19,759
New +$167K ﹤0.01% 2585

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

T. Rowe Price Associates's ABCL Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 1,587,870 shares worth $12.5M. The stake represents ﹤0.01% of the portfolio and ranks #1278 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in ABCL as recently as Q1 2023.

T. Rowe Price Associates first reported a position in ABCL in Q2 2022 and has held it in 5 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • T. Rowe Price Associates held 1,587,870 shares of AbCellera Biologics worth $12.5M as of Q2 2026.
  • AbCellera Biologics was a new T. Rowe Price Associates position in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1278 holding.
  • T. Rowe Price Associates first reported a position in AbCellera Biologics in Q2 2022 and has held it in 5 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.